Navigation Links
Study finds support for PCI in unprotected left main disease
Date:3/31/2008

significant difference in mortality may support PCI as an alternative option to bypass surgery, said Seung-Jung Park, MD, PhD, director of interventional cardiology at Asan Medical Center, Seoul, Korea. It is also worth noting that most of patients treated with drug-eluting stents who need target vessel revascularization can be treated with subsequent PCI, without significant increase of death or serious complications.

For the study, Dr. Park and his colleagues analyzed data from 2,240 patients with unprotected left main coronary artery disease treated at 12 medical centers in Korea. Of these, 318 were treated with bare-metal stents, 784 were treated with drug-eluting stents, and 1,138 underwent bypass surgery. During three years of follow-up, patients treated with bare-metal stents were nearly 11 times as likely to need a repeat procedure to reopen the target vessel when compared to those who underwent bypass surgery. However, the rates of death (hazard ratio: 1.04) and the combined rates of death, heart attack and stroke (hazard ratio: 0.86) were similar in the two groups. Patients treated with drug-eluting stents were nearly six times as likely to need a repeat procedure during three years of follow-up, but the rates of death (hazard ratio 1.36) and the combined rates of death, heart attack and stroke (hazard ratio: 1.40) were statistically similar, although there was a trend toward higher event rates with drug-eluting stents.

The next step is to test the studys findings in a more rigorous clinical trial, Dr. Park said. Based on these observations, a randomized trial comparing PCI with drug-eluting stents and CABG is warranted in patients with unprotected left main disease who are candidates for revascularization, he said. However, unprotected left main stenting should not be attempted in clinical practice before the physician has achieved specialized experiences.

Dr. Park will present the results of the Revascularization for Unprotect
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...-five day OnBase deployment critical in electronic...efit patients, CLEVELAND, July 9 /PRNewswire/ -- ...rise document management software suite, announced...sults since the deployment of,OnBase in March. Bas... four,states, SSM is a forward-thinking health car...
(Date:7/9/2008)...NTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX...and services to the global life,sciences markets, ...f,Canada Limited (AECL) with notice of arbitration...el AECL to fulfill its contractual obligations,und... (ILTSA) and if not,granted, seeking significant m...
(Date:7/9/2008)... DRE, Inc., a premier internation...s its customers that as much as $250,000 in medica...come tax filings. , Louis...mulus Act of 2008, in accordance with Tax Code Sec...al equipment bought in 2008. This could make 2008 ...
(Date:7/9/2008)... InsuranceSpecialists.com, a lead...or almost a decade, now offers comprehensive infor...idential candidates are taking on health reform as...ment-free, supplies unbiased material on medical, ...elp consumers make the best choices in coverage fo...
Breaking Medicine News(10 mins):Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 2Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 3Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3Health News:Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 3
...ir findings in the current Biology online on Febru...f a protein that plays// key roles in the control ...hibitor can halt the growth of tumors in mice and ...e. The findings are reported in companion papers...
...latest issue of the medical journal The Lancet cla...fects on arthritics//. This research carried out b...ience Foundation independently. Patients sufferin...oidal anti-inflammatories (NSAIDS) like Aspirin an...
...ucted by British researchers, breast fed babies ha...ed counterparts//. This once again goes on to prov...tudy was conducted by Institute of Child Health in...group of four to six. In this group, 184 children...
...vasively identify women at risk for preterm birth,...tal adrenal glands//, according to an abstract pre...he Society for Maternal-Fetal Medicine Conference ... major public health problem with lasting repercus...
Other Medicine News:Health News:New Protein Inhibitor Halts Growth Of Cancerous Cells 2
(Date:7/6/2008)...rketing Authorization Application currently ...E, July 7 /- Cell Therapeut...ced the publication of results from its,randomized...poliglumex,CT-2103) with gemcitabine or vinorelbi...) patients with previously untreated non-small cel...
(Date:7/3/2008)...ewswire-USNewswire/ -- All newborn infants,should ...esent at birth,according to a new recommendation ...recommendation and the accompanying summary of evi...Children whose hearing is impaired at birth, durin...with verbal and nonverbal communication and,social...
(Date:7/3/2008)...MBRIDGE Massachusetts, July 3,/PRNewswire-FirstCal...ology company, Jerini AG for an equity purchase p...a (HAE) product, FIRAZYR(R), to its Human Genetic... global sales expected to be around $350-400 mill...ve environment, - Expected to be accretive for No...
(Date:7/2/2008)...y Endpoint Met in Stage 1 of Two-Stage Study ...ble Patients to Date Continue to Show Objective Tu...e -, TUSTIN, Calif., July 2 /PRNewswire-FirstCall...M ) today reported that its lead product,candidate...imary endpoint,in its ongoing Phase II clinical tr...
Breaking Medicine Technology:Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Task Force Recommends Screening for Hearing Loss in All Newborns 2Task Force Recommends Screening for Hearing Loss in All Newborns 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 2Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 3Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 4CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 1CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 3International study strengthens case for daily calcium pill 195 1International study strengthens case for daily calcium pill 195 2Methamphetamine study suggests increased risk for HIV transmission 192 1Methamphetamine study suggests increased risk for HIV transmission 192 2Embryonic Stem Cells Repair Human Heart 190 1Embryonic Stem Cells Repair Human Heart 190 2Embryonic Stem Cells Repair Human Heart 190 3
...Presented at Society of Nuclear,Medicine Annual Me...stCall/ --,Immunomedics, Inc. , a biopharmaceutica...ies to treat cancer and other serious,diseases, to...en,(CEA) antibody, labetuzumab, labeled with the r...active when given in two doses,to patients with co...
...omide in Multiple Myeloma,Presented at the America..., CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ --...ults of a Phase III study,demonstrating that the a...s overall survival (OS) by 17.6 months in patients...eloma compared to the,current standard of care. Th...
Other Medicine Technology:Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 2Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 3Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 4Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 6
...ecifically to enable direct inspection of the peri... applications as well. Its insertion tube and dist...nsertion into the peripheral bronchi can be accomp...ated scope offers high-resolution and brightness, ...
Double lumen tubes for selective one-lung ventilation., ,Each SHER-I-BRONCH Endobronchial Tube is packaged with pre-loaded stylet, tube-to-circuit adaptors, suction catheters and Accessories Pack (f
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. The set consists of an endobronchial blocker catheter and an Arndt Multiport Airway Adapte
...tablish emergency airway access through the cricot...s a 12 gauge x 3" Angiocath I.V. catheter, which i...to ventilate. Designed to be used with the liter f...milar to the Cook Emergency Cricothyrotomy Kit, bu...
Medicine Products: